Therapeutic | Suvizumab |
Target | HIV-1 gp120 |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNSWIGWFRQAPGQGLEWIGDIYPGGGYTNYNEIFKGKATMTADTSTNTAYMELSSLRSEDTAVYYCSRGIPGYAMDYWGQGTLVTVSS |
Light Chain | DIQMTQRPDSLSASVGDRVTMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPWTFGQGTKVEIK |
100% seqID Fv Structure | 3ntc [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3ntc [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-I |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | Kaketsuken, Kumamoto University, University of Missouri-Columbia |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | HIV-1 infections |
Notes |